机译:Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia;
Kingston Hlth Sci Ctr, Kingston, ON, Canada;
Peter MacCallum Canc Ctr, Melbourne, Vic, AustraliaCent West Canc Care Ctr, Orange Hlth Serv, Orange, NSW, AustraliaMonash Univ, Melbourne, Vic, AustraliaWaikato Dist Hlth Board, Hamilton, New ZealandRoyal Adelaide Hosp, Adelaide, SA, AustraliaRoyal Cornwall Hosp, Truro, Cornwall, EnglandDana Farber Canc Inst, 450 Brookline Ave,DA917, Boston, MA 02215 USAPort Macquarie Base Hosp, Port Macquarie, NSW, AustraliaBC Canc Agcy, Vancouver, BC, CanadaGuys & St Thomas NHS Fdn Trust Biomed Res Ctr, CRUK, London, EnglandChris OBrien Lifehouse RPA, Sydney, NSW, AustraliaSt Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, AustraliaAuckland City Hosp, Auckland, New ZealandUniv Sydney, Sydney, NSW, AustraliaCanc Trials Ireland, Dublin, IrelandANZUP Canc Trials Grp, Sydney, NSW, AustraliaCross Canc Inst, Edmonton, AB, CanadaAdelaide Canc Ctr, Adelaide, SA, AustraliaQueens Univ, Canadian Canc Trials Grp CCTG, Kingston, ON, CanadaUniv Ottawa, Ottawa, ON, Canada;
Metachronous; Low volume; Enzalutamide; Metastatic hormone-sensitive prostate cancer;